Shares in Allergy Therapeutics fell 14 per cent on Monday, partly on the back of investor disappointment that US regulatory delays to the company's experimental hayfever vaccines had not been lifted.

Paul Cuddon, analyst at KBC Peel Hunt, said: “People speculated they [Allergy] were going to get the clinical trial hold lifted but it hasn't been.” There was little clarity on the potential timing of a decision.